

VGI Health Technology Limited further updates Sunset Date for sale of Invictus BioPharma Pty Ltd

Sydney New South Wales, 21 December 2022 – On 5 April 2022, the Directors of VGI Health Technology Limited (the **Company** or **VTL**) announced the sale of its wholly owned subsidiary, Invictus BioPharma Pty Ltd to Invictus BioPharma Holdings Ltd (**IVBHL**) (the **Transaction**). Shareholders of VTL subsequently approved the transaction at a general meeting held on 3 June 2022.

To enable the Transaction to be completed, VTL and IVBHL have agreed to extend the Sunset Date from 31 December 2022 to 31 March 2023.

This announcement was authorised for release by the board of the Company.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed company (NSX:VTL). VTL refers to recent announcements about the divestment of its wholly owned subsidiary Invictus BioPharma Pty Ltd. Post completion of this transaction, VTL will be focussed on manufacturing, marketing and selling novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery and exercise endurance. The Company has a product development program for evidence-based nutraceuticals.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:

https://www.nsx.com.au/broker_list_print.asp